Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Kentucky: - Baptist Health Hardin — Elizabethtown, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
- The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Kentucky: - CommonSpirit Saint Joseph Hospital - Bardstown — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- CommonSpirit Saint Joseph Hospital - Lexington — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- CommonSpirit Saint Joseph Medical Center - East Lexington — Lexington, Kentucky
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Kentucky: - Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
- University of Kentucky/Markey Cancer Center — Lexington, Kentucky
- The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Kentucky: - St Elizabeth Healthcare — Edgewood, Kentucky
- Norton Cancer Institute — Louisville, Kentucky
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Kentucky: - University of Kentucky Chandler Medical Center ( Site 0048) — Lexington, Kentucky
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Kentucky: - University of Kentucky Chandler Medical Center ( Site 0048) — Lexington, Kentucky
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Kentucky: - University of Louisville Health - James Graham Brown Cancer Center — Louisville, Kentucky
- Norton Cancer Institute — Louisville, Kentucky
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Kentucky: - Saint Elizabeth Healthcare Edgewood — Edgewood, Kentucky
- Saint Elizabeth Healthcare Fort Thomas — Fort Thomas, Kentucky
Phase 2 Recruiting Industry
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…
Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Kentucky: - St. Elizabeth Healthcare — Edgewood, Kentucky
- University Medical Center, lnc.:DBA University of Louisville Hospital — Louisville, Kentucky
- University of Louisville — Louisville, Kentucky
- UofL Health Brown Cancer Center — Louisville, Kentucky
Phase 2 Recruiting NIH
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691465
Sites in Kentucky: - University of Kentucky/Markey Cancer Center — Lexington, Kentucky
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Kentucky: - Exelixis Clinical Site #122 — Louisville, Kentucky
Phase 1 Recruiting Industry
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …
Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Kentucky: - UK Markey Cancer Center — Lexington, Kentucky
Recruiting Industry
The study is a prospective, multi-center, single cohort study involving up to 10 urological clinics in the US. After provision of informed consent, up to 20 mL of whole blood will be collected from each subject. The samples will be blinded…
Sponsor: Sequenom, Inc.
NCT ID: NCT07543757
Sites in Kentucky: - Graves Gilbert Clinic — Bowling Green, Kentucky
NA Recruiting Academic/Other
This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood…
Sponsor: University of Kentucky
NCT ID: NCT07594002
Sites in Kentucky: - University of Kentucky — Lexington, Kentucky